Hot Life Science Investor Mandate 2: Corporate VC of a Taiwanese Pharmaceutical Co. Seeking Opportunities Globally

5 Nov

A Taiwan-based investment firm is an evergreen fund and is the venture capital arm of a listed Taiwanese pharmaceutical company. The firm makes direct equity investments into venture stage companies, typically in Series A and B. The initial allocation ranges from $1-5 million. The firm is currently seeking opportunities based in Taiwan, China, Europe and the US.

The firm focuses 50% on therapeutics, 30% on medical devices, and 20% on other health technology. Within therapeutics, the firm considers small molecules and biologics in Oncology, CNS, pain, rare disease, and anti-infectives. The firm typically invests in preclinical projects that have proof-of-concept data and are within 2 years prior to phase 1 trial. Within medical devices, the firm is interested in innovative minimally invasive surgical tools for patient or bedside use such as point-of-care diagnostics.

The firm is looking for experienced management teams with strong scientific expertise and management skills. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: